US2010233304A1PendingUtilityA1
Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
Est. expiryJan 4, 2028(~1.4 yrs left)· nominal 20-yr term from priority
Inventors:Yuanlong Pan
A61P 9/10A61P 39/06A61P 25/28A61P 25/00A61P 3/02A23D 9/007A61K 31/454A23L 33/12A61K 31/198A61K 31/675A23L 33/115A61K 31/202A61K 45/06A61K 31/20A61K 31/54A61K 36/16A23K 50/40A61K 31/56A61K 35/60A23K 10/18A61K 31/4375A61K 31/683A23L 33/175A61K 31/522A61K 31/445A61K 31/55A23K 20/158A61K 31/663A61K 31/22
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compositions comprising one or more unsaturated fatty acids and one or more nitric oxide releasing compounds, and methods for using such compositions for enhancing cognitive function, reducing or preventing a decline of social interaction, reducing or preventing age-related behavioral changes, increasing trainability, maintaining optimal brain function, facilitating learning and memory, reducing memory loss, retarding brain aging, preventing or treating strokes, and preventing or treating dementia in an animal. Preferably, the compositions are food compositions useful for enhancing cognitive function in humans and companion animals.
Claims
exact text as granted — not AI-modified1 . A composition suitable for enhancing cognitive and related functions in an animal comprising one or more unsaturated fatty acids (UFA) and one or more nitric oxide releasing compounds (NORC) in an amount effective for enhancing cognitive and related functions in an animal.
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . (canceled)
26 . A method for enhancing cognitive function in an animal comprising administering a composition comprising one or more unsaturated fatty acids (UFA) and one or more nitric oxide releasing compounds (NORC) to the animal in an amount effective for enhancing cognitive function in the animal.
27 . (canceled)
28 . (canceled)
29 . The method of claim 26 wherein the animal is an aging animal.
30 . The method of claim 26 wherein the UFA comprises one or more of a natural fish oil, ALA, EPA, DPA, DHA, or another n-3 fatty acid from any source.
31 . (canceled)
32 . The method of claim 26 wherein the composition comprises from about 0.1% to about 50% UFA.
33 . (canceled)
34 . (canceled)
35 . (canceled)
36 . The method of claim 26 wherein the composition comprises from about 0.1% to about 20% NORC.
37 . (canceled)
38 . (canceled)
39 . (canceled)
40 . (canceled)
41 . (canceled)
42 . (canceled)
43 . (canceled)
44 . (canceled)
45 . The method of claim 26 wherein the composition is administered to the animal in conjunction with one or more cognitive drugs in an amount effective for enhancing cognitive function.
46 . The method of claim 45 wherein the cognitive drug is one or more of selegiline, nicerogoline, a phosphatidylserine, propentofyline, galantamine, vinpocetine, donepezil, a Ginkgo biloba extract, a bisphosophonate, raloxifene, an estrogen, a phytoestrogen, calcitonin, risedronate, or alendronate.
47 . (canceled)
48 . The method of claim 26 wherein the composition is administered on an extended regular basis.
49 . The method of claim 48 wherein the composition is administered to the animal on a daily basis.
50 . The method of claim 26 wherein the animal is an aging animal.
51 . The method of claim 50 wherein the animal has a phenotype associated with age-related cognitive impairment.
52 . The method of claim 51 wherein the phenotype includes one or more of decreased ability to recall, short-term memory loss, decreased learning rate, decreased capacity for learning, decreased problem solving skills, decreased attention span, decreased motor performance, increased confusion, or dementia, as compared to a control animal not having the phenotype.
53 . (canceled)
54 . (canceled)
55 . (canceled)
56 . (canceled)
57 . (canceled)
58 . (canceled)
59 . (canceled)
60 . (canceled)
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)
68 . (canceled)
69 . (canceled)
70 . (canceled)
71 . (canceled)
72 . (canceled)
73 . (canceled)
74 . (canceled)
75 . (canceled)
76 . (canceled)
77 . (canceled)
78 . (canceled)
79 . (canceled)
80 . (canceled)
81 . (canceled)
82 . (canceled)
83 . (canceled)
84 . (canceled)
85 . (canceled)
86 . (canceled)
87 . (canceled)
88 . (canceled)
89 . (canceled)
90 . (canceled)
91 . (canceled)
92 . (canceled)
93 . (canceled)
94 . (canceled)
95 . (canceled)
96 . (canceled)
97 . (canceled)
98 . (canceled)
99 . (canceled)
100 . (canceled)
101 . (canceled)
102 . (canceled)
103 . (canceled)
104 . (canceled)
105 . (canceled)
106 . (canceled)
107 . (canceled)
108 . (canceled)
109 . (canceled)
110 . A method for preventing or treating strokes in an animal comprising administering a composition comprising UFA and NORC to the animal in an amount effective to prevent or treat strokes.
111 . The method of claim 110 wherein the animal is a human or companion animal.
112 . The method of claim 110 wherein the animal is an aging animal.
113 . (canceled)
114 . (canceled)
115 . (canceled)
116 . (canceled)
117 . (canceled)
118 . (canceled)
119 . (canceled)
120 . (canceled)
121 . (canceled)
122 . (canceled)
123 . (canceled)
124 . (canceled)
125 . (canceled)
126 . (canceled)
127 . (canceled)
128 . (canceled)
129 . (canceled)
130 . (canceled)
131 . (canceled)
132 . (canceled)
133 . (canceled)
134 . (canceled)
135 . (canceled)
136 . (canceled)
137 . (canceled)
138 . (canceled)
139 . (canceled)
140 . (canceled)
141 . (canceled)
142 . (canceled)
143 . (canceled)
144 . (canceled)
145 . (canceled)
146 . (canceled)
147 . (canceled)
148 . (canceled)
149 . (canceled)
150 . (canceled)
151 . (canceled)
152 . (canceled)
153 . (canceled)
154 . (canceled)
155 . (canceled)
156 . (canceled)
157 . (canceled)
158 . (canceled)
159 . (canceled)
160 . (canceled)
161 . (canceled)
162 . (canceled)
163 . (canceled)
164 . (canceled)
165 . (canceled)
166 . (canceled)
167 . (canceled)
168 . (canceled)
169 . (canceled)
170 . (canceled)
171 . (canceled)
172 . (canceled)
173 . (canceled)
174 . (canceled)
175 . (canceled)
176 . (canceled)
177 . (canceled)
178 . (canceled)
179 . (canceled)
180 . (canceled)
181 . (canceled)
182 . (canceled)
183 . (canceled)
184 . (canceled)
185 . (canceled)
186 . (canceled)
187 . (canceled)
188 . (canceled)
189 . (canceled)
190 . (canceled)
191 . (canceled)
192 . (canceled)
193 . (canceled)
194 . (canceled)
195 . (canceled)
196 . The method of claim 26 wherein the NORC is arginine, citrulline, citrulline, or a nitric oxide-releasing derivatives thereof.
197 . The method of claim 26 wherein the composition further comprises one or more B vitamins in an amount effective for enhancing cognitive function, one or more antioxidants in an amount effective for enhancing cognitive function, or both.
198 . The method of claim 197 wherein the composition comprises from about 0.1 to 40 times the recommended daily requirement of B vitamins, from about 0.0001% to about 25% of antioxidants, or both.
199 . The method of claim 110 wherein the NORC is arginine, citrulline, citrulline, or a nitric oxide-releasing derivatives thereof.Join the waitlist — get patent alerts
Track US2010233304A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.